Methods and compositions related to the modulation of intercellular junctions

2-14. (canceled)

A method for enhancing the delivery of a biologically active molecule through a cell barrier, comprising:

• administering to a subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the intercellular junction disruption agent is administered prior to or after the administration of the biologically active molecule, and wherein the delivery of the biologically active molecule is enhanced.

-34. (canceled)

A method for treating a subject, comprising:

• administering to the subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the subject has an infection or an infection related disorder, and wherein the intercellular junction disruption agent is a heparan sulfate-like glycosaminoglycan, a heparin-like glycosaminoglycan or an enzyme that degrades heparan sulfate-like glycosaminoglycans or heparin-like glycosaminoglycans or some combination thereof.

-42. (canceled)

A method for treating a subject, comprising:

• administering to the subject a glycosaminoglycan-degrading enzyme and a biologically active molecule, wherein the subject has a respiratory disorder.

-53. (canceled)

A method for treating a subject, comprising:

• administering to the subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the subject has an ocular disorder, an immunologic disorder that is not rheumatoid arthritis or psoriasis, or a dermatologic disorder that is not psoriasis, and wherein when the subject has an ocular disorder, the intercellular junction disruption agent is a chondroitin sulfate glycosaminoglycan or a chondroitinase.

-76. (canceled)

A method for enhancing the delivery of a biologically active molecule through the blood-brain barrier, comprising:

• administering to a subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, and wherein the intercellular junction disruption agent or biologically active molecule is linked to a molecule that targets the blood-brain barrier.

-81. (canceled)

A method for enhancing the delivery of a biologically active molecule through the blood-brain barrier, comprising:

• administering to a subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, and wherein the intercellular junction disruption agent or biologically active molecule is administered via the internal carotid artery.

(canceled)

A method for enhancing the delivery of a biologically active molecule through the blood-brain barrier, comprising:

• administering to a subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the biologically active molecule is an agent for treating a central nervous system disorder, and wherein the delivery of the biologically active molecule is enhanced.

A method for enhancing the delivery of a biologically active molecule to a subject, comprising:

• administering to the subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the administration is ocular, via the nasal tract or via the skin, sublingual tissue or gastrointestinal tissue, and wherein the delivery of the biologically active molecule is enhanced.

-94. (canceled)

A method for enhancing the delivery of a biologically active molecule through the upper or lower respiratory tract in a subject, comprising:

• administering to the subject via the upper or lower respiratory tract a glycosaminoglycan-degrading enzyme, and a biologically active molecule.

-166. (canceled)

A composition, comprising:

• an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the biologically active molecule is an agent for treating central nervous system disorders, and wherein the intercellular junction disruption agent is not a chondroitinase ABC I-generated chondroitin sulfate fragment or chondroitinase ABC I.

(canceled)

A composition, comprising:

• an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the biologically active agent is an agent for treating an infection or an infection related disorder, and wherein the intercellular junction disruption agent is a heparan sulfate-like glycosaminoglycan, a heparin-like glycosaminoglycan, or an enzyme that degrades heparan sulfate-like glycosaminoglycans or heparin-like glycosaminoglycans or some combination thereof.

-171. (canceled)

A composition, comprising:

• an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the biologically active agent is an agent for treating a respiratory disorder, an ocular disorder, an immunologic disorder that is not rheumatoid arthritis or psorasis, or a dermatolozic disorder that is not psoriasis, and wherein when the biologically active agent is an agent for treating an ocular disorder, the intercellular junction disruption agent is a chondroitin sulfate glycosaminoglycan or a chondroitinase.

-178. (canceled)

A composition, comprising:

• an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, and wherein the intercellular junction disruption agent or biologically active molecule is linked to a molecule that targets the blood-brain barrier.

A composition, comprising:

• an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the composition is in a form suitable for administration to the eye, nasal administration, topical administration or sublingual, vaginal or rectal delivery, and wherein the form suitable for nasal administration is a nasal spray, nasal drop or nasal gel, and wherein the form suitable for topical administration is an ointment, lotion, spray, gel, cream, swab, wipe, bandage or patch, and wherein the form suitable for sublingual delivery is a sublingual tablet or oral gel.

-187. (canceled)

A composition, comprising:

• an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan-degrading enzyme wherein the composition is in a form suitable for pulmonary delivery, and wherein the form suitable for pulmonary delivery is an inhaler.

-191. (canceled)

A composition, comprising:

• an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, and wherein the composition is in an enteric tablet or capsule.